Paper · 41520078
Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.
Czyrek AA and 13 others. Mol Biomed, 2026. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes. Papers, record 41520078. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41520078
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Engineered fibroblast growth factor 1 variants uncouple glucose-lowering effects from mitogenic activity with therapeutic potential for type 2 diabetes.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Diabetes Mellitus, Type 2 | Major topic |
| Fibroblast Growth Factor 1 | Major topic |
| Protein Engineering | Major topic |
| Mitogens | Major topic |
| Hypoglycemic Agents | Major topic |
| Animals | |
| Humans | |
| Mice | |
| Cell Proliferation | |
| Blood Glucose | |
| Male |
Source PubMed
Grants8
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| POIR.04.01.04.-00-0117/15 | Narodowe Centrum Badań i Rozwoju | PubMed | ||
| LX22NPO5102 | Národní ústav pro výzkum rakoviny (CZ) | PubMed | ||
| LUAUS23295 | Ministerstvo Školství, Mládeže a Tělovýchovy | PubMed | ||
| GF21-26400K | Grantová Agentura České Republiky | PubMed | ||
| GF25-15902K | Grantová Agentura České Republiky | PubMed | ||
| Praemium Academiae | Akademie Věd České Republiky | PubMed | ||
| Weave-Unisono 2024/06/Y/NZ1/00089 | Narodowe Centrum Nauki | PubMed | ||
| IDUB 16/2022 | Ministry of Education and Science, Poland | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16,597,617 | Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. | J Biol Chem | 2006 | https://conductscience.org/library/papers/16597617 | PubMed |
| 2 | 26,483,756 | Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. | Front Endocrinol (Lausanne) | 2015 | https://conductscience.org/library/papers/26483756 | PubMed |
| 3 | 31,091,809 | Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. | Cells | 2019 | https://conductscience.org/library/papers/31091809 | PubMed |
| 4 | 15,574,884 | Phosphorylation-regulated nucleocytoplasmic trafficking of internalized fibroblast growth factor-1. | Mol Biol Cell | 2005 | https://conductscience.org/library/papers/15574884 | PubMed |
| 5 | 29,983,915 | A threshold model for receptor tyrosine kinase signaling specificity and cell fate determination. | F1000Res | 2018 | https://conductscience.org/library/papers/29983915 | PubMed |
| 6 | 36,161,959 | Autocrine FGF1 signaling promotes glucose uptake in adipocytes. | Proc Natl Acad Sci U S A | 2022 | https://conductscience.org/library/papers/36161959 | PubMed |
| 7 | 22,522,926 | A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. | Nature | 2012 | https://conductscience.org/library/papers/22522926 | PubMed |
| 8 | 14,681,378 | The Pfam protein families database. | Nucleic Acids Res | 2004 | https://conductscience.org/library/papers/14681378 | PubMed |
| 9 | 23,403,721 | Exploring mechanisms of FGF signalling through the lens of structural biology. | Nat Rev Mol Cell Biol | 2013 | https://conductscience.org/library/papers/23403721 | PubMed |
| 10 | 19,247,306 | The FGF family: biology, pathophysiology and therapy. | Nat Rev Drug Discov | 2009 | https://conductscience.org/library/papers/19247306 | PubMed |
1 to 10 of 52
See all 52 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,511,911 | The Role of FGF1 in Chronic Liver Diseases. | Biomedicines | 2026 | https://conductscience.org/library/papers/42511911 | PubMed |
| 42,387,574 | Structure-function relationship in FGF signaling: rational design of highly stable FGF2 variants and their effect on cell growth, metabolism, and survival. | J Biol Eng | 2026 | https://conductscience.org/library/papers/42387574 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41520078
GET https://conductscience.org/api/papers/v1/41520078/references?page=2